廣告
香港股市 將在 4 小時 開市

  • 恒指

    18,578.30
    +102.38 (+0.55%)
     

  • 國指

    6,572.45
    +25.16 (+0.38%)
     

  • 上證綜指

    3,140.72
    +35.90 (+1.16%)
     

  • 道指

    38,852.27
    +176.59 (+0.46%)
     

  • 標普 500

    5,180.74
    +52.95 (+1.03%)
     

  • 納指

    16,349.25
    +192.92 (+1.19%)
     

  • Vix指數

    13.49
    0.00 (0.00%)
     

  • 富時100

    8,213.49
    +41.34 (+0.51%)
     

  • 紐約期油

    78.69
    +0.58 (+0.74%)
     

  • 金價

    2,332.90
    +24.30 (+1.05%)
     

  • 美元

    7.8169
    +0.0066 (+0.08%)
     

  • 人民幣

    0.9216
    -0.0048 (-0.52%)
     

  • 日圓

    0.0506
    -0.0003 (-0.51%)
     

  • 歐元

    8.4172
    +0.0109 (+0.13%)
     

  • Bitcoin

    63,512.55
    -287.82 (-0.45%)
     

  • CMC Crypto 200

    1,364.74
    +52.11 (+3.97%)
     

Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2 分鐘文章

For the quarter ended March 2024, Labcorp (LH) reported revenue of $3.18 billion, down 15.9% over the same period last year. EPS came in at $3.68, compared to $3.82 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.13 billion, representing a surprise of +1.59%. The company delivered an EPS surprise of +6.36%, with the consensus EPS estimate being $3.46.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

廣告

Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Biopharma Laboratory Services: $710.90 million versus $697.35 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -49.3% change.

  • Revenues- Diagnostics Laboratories: $2.48 billion compared to the $2.42 billion average estimate based on three analysts. The reported number represents a change of +4.1% year over year.

  • Adjusted Operating Income- Biopharma Laboratory Services: $99.90 million compared to the $92.47 million average estimate based on three analysts.

  • Adjusted Operating Income- Diagnostics Laboratories: $417.90 million versus $427.90 million estimated by three analysts on average.

View all Key Company Metrics for Labcorp here>>>

Shares of Labcorp have returned -4% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Labcorp (LH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research